"Not So Different" Episode 5: Policy and Biosimilars

“If legislators want to be able to tell their constituents that they acted on drug prices this year, this is the vehicle to do it. There is nothing else with this kind of support and with this kind of impact sitting before legislators right now,” said Christine Simmon, JD, executive director of the Biosimilars Council, about the bipartisan CREATES Act.
March 20, 2018
Our guest on this episode of “Not So Different” is Christine Simmon, JD, the executive director of the Association for Accessible Medicines’ (AAM) Biosimilars Council.

Simmon joined The Center for Biosimilars® via phone to discuss recent comments from FDA Commissioner, Scott Gottlieb, MD, on challenges in the US biosimilars market, and a potential legislative solution—the bipartisan CREATES Act—that could help to address some of those challenges.



Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.